Mauna Kea: a breakthrough in pancreatic cysts

(CercleFinance.com) - Mauna Kea gained nearly 6% on Tuesday on the Paris Bourse as its Cellvizio endomicroscopy platform was recommended by the European Society of Gastrointestinal Endoscopy (ESGE) for the diagnosis of pancreatic cysts.


The European Society of Gastrointestinal Endoscopy (ESGE) has issued a recommendation in favor of the use of needle confocal laser endomicroscopy (nCLE) with Cellvizio for the characterization of cystic lesions of the pancreas.

From Mauna Kea's perspective, this distinction promotes its integration as standard clinical practice and marks a major step towards wider commercial adoption.

The year 2025 is off to a strong start, and should be a decisive year for this indication", comments Sacha Loiseau, CEO of the French medtech company.

He points out that the results of the CLIMB study - the largest clinical trial for this indication - conducted in 14 referral centers in the USA, will be unveiled in May, during Digestive Disease Week.

According to the CEO, these data will definitively establish Mauna Kea's technology as 'the world reference for the characterization of pancreatic cysts'.

Copyright (c) 2025 CercleFinance.com. All rights reserved.